IP Library › Granted Patent US 12,410,215
Granted Patent B2
US 12,410,215 · App. 19/053,784 · Granted Sep 9, 2025

Mutated glycoprotein of vesicular stomatitis virus

Inventors: Aurélie Albertini (Gometz le Chatel, FR); Yves Gaudin (Paris, FR); Hélène Raux (Antony, FR); Laura Belot (Maurepas, FR); Jovan Nikolic (Paris, FR)
Assignees: Centre National de la Recherche Scientifique (CNRS); Université Paris-Saclay
C07K14/005C12N7/00C12N2760/20222C12N2760/20232C12N2760/20245C12N2760/20262
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,215
App. No.
19/053,784
Granted
Sep 9, 2025
Kind
B2
Abstract

The invention relates to an isolated non-naturally occurring protein comprising the amino acid sequence as set forth in SEQ ID NO: 1, and wherein the amino acid in position 8, 47, 209 and/or 354 is substituted by any amino acid different from the amino acid indicated at that position in said sequence SEQ ID NO: 1.

Claims (32)

1. A polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide comprises an amino acid mutation at position 47 and an amino acid mutation at position 354.

2. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 96% identical to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide comprises an amino acid mutation at position 47 and/or an amino acid mutation at position 354.

3. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 97% identical to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide comprises an amino acid mutation at position 47 and/or an amino acid mutation at position 354.

4. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 98% identical to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide comprises an amino acid mutation at position 47 and/or an amino acid mutation at position 354.

5. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide comprises an amino acid mutation at position 47 and/or an amino acid mutation at position 354.

6. The polypeptide of claim 2 , wherein the polypeptide comprises:

(a) an amino acid mutation at position 47 and position 354; or

(b) an amino acid mutation at position 47 or position 354.

7. A nucleic acid molecule encoding the polypeptide of claim 1 .

8. A nucleic acid molecule encoding the polypeptide of claim 2 .

9. A nucleic acid molecule encoding the polypeptide of claim 3 .

10. A nucleic acid molecule encoding the polypeptide of claim 4 .

11. A nucleic acid molecule encoding the polypeptide of claim 5 .

12. A nucleic acid molecule encoding the polypeptide of claim 6 .

13. A recombinant virus expressing the polypeptide of claim 1 .

14. A recombinant virus expressing the polypeptide of claim 2 .

15. A recombinant virus expressing the polypeptide of claim 3 .

16. A recombinant virus expressing the polypeptide of claim 4 .

17. A recombinant virus expressing the polypeptide of claim 5 .

18. A recombinant virus expressing the polypeptide of claim 6 .

19. A composition comprising the polypeptide of claim 1 .

20. A composition comprising the polypeptide of claim 2 .

21. A composition comprising the polypeptide of claim 3 .

22. A composition comprising the polypeptide of claim 4 .

23. A composition comprising the polypeptide of claim 5 .

24. A composition comprising the polypeptide of claim 6 .

25. A membrane comprising the polypeptide of claim 1 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

26. A membrane comprising the polypeptide of claim 2 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

27. A membrane comprising the polypeptide of claim 3 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

28. A membrane comprising the polypeptide of claim 4 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

29. A membrane comprising the polypeptide of claim 5 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

30. A membrane comprising the polypeptide of claim 6 , wherein the polypeptide is anchored in the membrane, and wherein the membrane is the membrane of a liposome, vesicle, exosome, or nanoparticle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2025
From: ALBERTINI, AURÉLIE; GAUDIN, YVES; RAUX, HÉLÈNE; BELOT, LAURA; NIKOLIC, JOVAN
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS); UNIVERSITÉ PARIS-SACLAY
Reel/Frame 070220/0570 →
Priority Claims (1)
EP 17306255 · Sep 22, 2017 · regional
Continuity (4)
Continuation 18629097 · Apr 8, 2024
Continuation 18473720 · Sep 25, 2023
Continuation 16649271
Related Publication 20250171504A1 · May 29, 2025
References Cited (38)
US 12030915B2 · Albertini et al. · 2024 [cited by applicant]
US 20080124357A1 · Yao et al. · 2008 [cited by applicant]
EP 2020444A1 · 2009 [cited by applicant]
JP 2005516607A · 2005 [cited by applicant]
JP 2005247757A · 2005 [cited by applicant]
JP 2010535495A · 2010 [cited by applicant]
JP 2016501528A · 2016 [cited by applicant]
WO 0119380A2 · 2001 [cited by applicant]
WO 2010040023A2 · 2010 [cited by applicant]
Finkelshtein et al., PNAS vol. 110, #18, pp. 7306-7311 (Year: 2013). [cited by examiner]
Albertini et al.(2012). Molecular and Cellular Aspects of Rhabdovirus Entry. Viruses 4, 117-139. [cited by applicant]
Amirache et al. (2014). Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 123, 1422-1424. [cited by applicant]
Ammayappan et al. (2013). Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands. J Virol 87, 13543-13555. [cited by applicant]
Barber, G.N. (2005). VSV-tumor selective replication and protein translation. Oncogene 24, 7710-7719. [cited by applicant]
Ferlin et al. (2014). Characterization of pH-sensitive molecular switches that trigger the structural transition of vesicular stomatitis virus glycoprotein from the postfusion state toward the prefusion state. J Virol 8… [cited by applicant]
Finkelshtein et al. ( 2013) . L DL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proceedings of the National Academy of Sciences of the United States of America 110, 730… [cited by applicant]
Roche et al. (2006). Crystal structure of the low-pH form of the vesicular stomatitis virus glycoprotein G. Science 313, 187-191. [cited by applicant]
Roche et al. (2007). Structure of the prefusion form of the vesicular stomatitis virus glycoprotein g. Science 315, 843-848. [cited by applicant]
Nikolic et al. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nature communications, 9(1), 2018, 1-12. [cited by applicant]
Ammayappan et al. “Characteristics of Oncolytic Vesicular Stomatitis Virus Displaying Tumor-Targeting Ligands” Journal of Virology vol. 87 No. 24 p. 13543-13555 (Year: 2013). [cited by applicant]
He et al., Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment. Front. Immunol. 14:1237764 (Year: 2023). [cited by applicant]
Messer et al. “Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders” Neurobiology of Disease 134 (2020) 104619. [cited by applicant]
Rose et al. “Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1” Journal of V… [cited by applicant]
Brown et al. “A Receptor Mediated Pathway for Cholesterol Homeostasis” Science, vol. 232, Apr. 4, 1986 p. 34-47. [cited by applicant]
Hastie et al. Oncolytic Vesicular Stomatitis Virus in an Immunocompetent Model of MUC1-Positive or MUC1-Null Pancreatic Ductal Adenocarcinoma Journal of Virology p. 10283-10294, Sep. 2013 vol. 87 No. 18. [cited by applicant]
Harper et al. “Purification of proteins fused to glutathione S-tranferase” Methods Mol Biol. 2011 ; 681: 259-280. doi:10.1007/978-1-60761-913-0_14. [cited by applicant]
Fernandez et al.. “Genetically Engineered Vesicular Stomatitis Virus in Gene Therapy: Application for Treatment of Malignant Disease” Journal of Virology, vol. 76, No. 2, Jan. 2002, p. 895-904. [cited by applicant]
Apr. 25, 2023 (JP) Decision of Refusal Application No. 2020-516534. [cited by applicant]
Aug. 30, 2022 (JP) Decision of Refusal Application No. 2020-516534. [cited by applicant]
Hastie et al. “Understanding and altering cell tropism of vesicular stomatitis virus” Virus Res. Sep. 2013; 176(1-2): 16-32. Epub, Jun. 22, 2013. [cited by applicant]
Rücker et al. “pH-dependent molecular dynamics of vesicular stomatitis virus glycoprotein G”. Proteins. Nov. 2012; 80 (11):2601-13. Epub Aug. 10, 2012. [cited by applicant]
Roche et al. “Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited”. Cell. Mol. Life Sci. 65 (2008), 1716¬-1728. [cited by applicant]
Buchholz et al. (2015) Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery. Trends in Biotechnology, 33 (12) 777-790. [cited by applicant]
Joglekar et al. “Pseudotyped Lentiviral Vectors: One Vector, Many Guises”. Human Gene Therapy Methods, 28 (6) 291-301, 2017. [cited by applicant]
Hwang et al. “Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors”. Gene Ther. 20(8): 807¬815, 2013. [cited by applicant]
Baquero et al. “Recent mechanistic and structural insights on class III viral fusion glycoproteins”. Current Opinion in Structural Biology 33:52-60, 2015. [cited by applicant]
Lillis et al. (2008) LDL Receptor-Related Protein 1: Unique Tissue¬Specific Functions Revealed by Selective Gene Knockout Studies. Physiol Rev 88: 887-918, httos://doi.ora/10.1152/ohvsrev.00033.2007. [cited by applicant]
Beglova et al. (2005) The LDL receptor: how acid pulls the trigger. Trends Biochem Sci. 30(6):309-17. [cited by applicant]